Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
US Department of Justice
Queensland Health
Farmers Insurance
AstraZeneca
QuintilesIMS
Deloitte
Cantor Fitzgerald
Daiichi Sankyo

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR NALMEFENE HYDROCHLORIDE

« Back to Dashboard

Clinical Trials for Nalmefene Hydrochloride

Trial ID Title Status Sponsor Phase Summary
NCT00000437 Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 4 The purpose of this study is to determine the effectiveness of naltrexone (Revia) in reducing drinking and smoking in patients with both nicotine and alcohol dependence. Individuals will be randomly assigned to a 12-week trial of a fixed daily dose of either naltrexone (Revia) and nicotine replacement patch or placebos. All individuals will receive weekly coping skills and smoking-cessation behavioral therapy. Followup interviews will be conducted 3 and 6 months after treatment to determine smoking and drinking status and persistence of any dependence symptoms.
NCT00000437 Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone) Completed The Scripps Research Institute Phase 4 The purpose of this study is to determine the effectiveness of naltrexone (Revia) in reducing drinking and smoking in patients with both nicotine and alcohol dependence. Individuals will be randomly assigned to a 12-week trial of a fixed daily dose of either naltrexone (Revia) and nicotine replacement patch or placebos. All individuals will receive weekly coping skills and smoking-cessation behavioral therapy. Followup interviews will be conducted 3 and 6 months after treatment to determine smoking and drinking status and persistence of any dependence symptoms.
NCT00000450 Naltrexone Maintenance Treatment of Alcoholism Completed National Institute on Alcohol Abuse and Alcoholism (NIAAA) Phase 4 The purpose of this study is to determine the long-term effectiveness of naltrexone treatment in alcohol-dependent patients who respond to short-term treatment. Those who respond to short-term treatment will be randomized to a 1-year, double-blind, placebo-controlled maintenance phase with a 6-month posttreatment followup.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Nalmefene Hydrochloride

Condition Name

Condition Name for Nalmefene Hydrochloride
Intervention Trials
Alcohol Dependence 10
Alcoholism 3
Pathological Gambling 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Nalmefene Hydrochloride
Intervention Trials
Alcoholism 13
Alcohol Drinking 4
Disease 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Nalmefene Hydrochloride

Trials by Country

Trials by Country for Nalmefene Hydrochloride
Location Trials
United States 5
Germany 4
France 4
Japan 3
Czech Republic 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Nalmefene Hydrochloride
Location Trials
Florida 2
Maryland 1
Connecticut 1
Minnesota 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Nalmefene Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Nalmefene Hydrochloride
Clinical Trial Phase Trials
Phase 4 3
Phase 3 6
Phase 2/Phase 3 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Nalmefene Hydrochloride
Clinical Trial Phase Trials
Completed 11
Recruiting 6
Active, not recruiting 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Nalmefene Hydrochloride

Sponsor Name

Sponsor Name for Nalmefene Hydrochloride
Sponsor Trials
H. Lundbeck A/S 9
National Institute on Alcohol Abuse and Alcoholism (NIAAA) 4
Otsuka Pharmaceutical Co., Ltd. 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Nalmefene Hydrochloride
Sponsor Trials
Industry 14
Other 14
NIH 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Citi
Dow
UBS
Medtronic
Johnson and Johnson
Healthtrust
Harvard Business School
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.